Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EBT (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed EBT for 16 consecutive years, with $66.1 million as the latest value for Q4 2025.

  • Quarterly EBT rose 75.34% to $66.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$28.4 million through Sep 2025, up 48.31% year-over-year, with the annual reading at -$438000.0 for FY2024, 99.11% up from the prior year.
  • EBT hit $66.1 million in Q4 2025 for Perspective Therapeutics, up from -$26.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $66.1 million in Q4 2025 to a low of -$26.0 million in Q3 2025.
  • Historically, EBT has averaged -$3.3 million across 5 years, with a median of -$8.4 million in 2022.
  • Biggest five-year swings in EBT: crashed 598.22% in 2023 and later surged 324.19% in 2024.
  • Year by year, EBT stood at -$1.6 million in 2021, then tumbled by 357.29% to -$7.3 million in 2022, then tumbled by 129.39% to -$16.8 million in 2023, then soared by 324.19% to $37.7 million in 2024, then skyrocketed by 75.34% to $66.1 million in 2025.
  • Business Quant data shows EBT for CATX at $66.1 million in Q4 2025, -$26.0 million in Q3 2025, and -$22.0 million in Q2 2025.